HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
XRbna1qWjAu2Hqd6